Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beam Therapeutics ( (BEAM) ) has issued an update.
On February 9, 2026, Beam Therapeutics entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to secure continued access to certain gene-editing patents originally licensed by Bio Palette from Kobe. The arrangement ensures Beam will receive a direct, exclusive license from Kobe to practice these patents if the original Kobe–Bio Palette license ends under specified conditions, with Beam agreeing to pay Kobe the financial amounts it would otherwise owe to Bio Palette under the existing sublicense terms.
This structure is designed to protect Beam’s core intellectual property position and reduce licensing risk around critical patents underpinning its base-editing programs. By putting this contingency in place, Beam strengthens the durability of its IP rights and operational continuity, which may be important for partners, investors, and other stakeholders relying on the stability of its gene-editing platform.
The most recent analyst rating on (BEAM) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.
Spark’s Take on BEAM Stock
According to Spark, TipRanks’ AI Analyst, BEAM is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, very large losses, and negative cash flows). Technicals are constructive with strong trend and positive MACD, but overbought RSI adds near-term risk. Corporate events are a meaningful positive (extended runway and regulatory/clinical progress), while valuation support is limited due to losses and a negative P/E.
To see Spark’s full report on BEAM stock, click here.
More about Beam Therapeutics
Beam Therapeutics Inc. is a biotechnology company focused on developing genetic medicines using base editing technology. Its work centers on leveraging licensed intellectual property, including key patents from academic institutions such as Kobe University, to support its therapeutic pipeline and maintain freedom to operate in the gene editing space.
Average Trading Volume: 1,874,199
Technical Sentiment Signal: Buy
Current Market Cap: $2.73B
Find detailed analytics on BEAM stock on TipRanks’ Stock Analysis page.